From: Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial
Response Assessment
Vaccine N = 10
DD + Vaccine N = 7
All N = 17
PR
1 (10 %)
0
1 (6 %)
SD
4 (40 %)
4 (57 %)
8 (47 %)
PD
5 (50 %)
3 (43 %)
Time to Progression
4.4 months
4.9 months
4.6 months